Innovations in the Treatment of Amyloidosis Suzanne Lentzsch M.D., PhD
Suzanne Lentzsch how John Theurer Cancer Center is innovating the treatment of patients with amyloidosis by taking a dual approach.
Changing the Future of Cancer through Collaboration
Through our partnership with the National Cancer Institute’s Immunology branch, Georgetown University’s Lombardi Comprehensive Cancer Center, the Parker Institute for Cancer Immunotherapy, and Memorial Sloan Kettering, we are propelling advances in novel anticancer treatments, including immunotherapy and cellular therapies. Progress in the development, assessment, and FDA approval of these treatments is happening at an accelerating pace, and you may be able to benefit from these innovative therapies right here at John Theurer Cancer Center.
A Commitment to Translational Research
Translational research (“bench-to-bedside”) efforts promote the extension of new developments from basic science research laboratories to the clinic, where they may help patients. In our David Joseph Jurist Center for Research and through our affiliations with Georgetown’s Lombardi Cancer Center, the Stevens Institute of Technology in New Jersey, and Memorial Sloan Kettering, we are dedicated to translational research. Our scientists are studying epigenetic factors that affect various cancers, novel approaches to improve outcomes following hematopoietic stem cell transplantation, and how immunotherapy can be influenced by immune cells and the microbiome. We are also opening a comprehensive translational science center and a new medical school in collaboration with Seton Hall University, in Nutley, New Jersey, at the former location of Hoffmann-La Roche.
Embracing Precision Medicine
Through our partnership with Memorial Sloan Kettering, we are using precision medicine to tailor the optimal type and sequence of treatment for each of our patients. Our combined clinical experience and resources will allow us to implement precision medicine in ways that benefit patients today and in the future.
Implementing Value-Based Care with Big Data
COTA (Cancer Outcomes Tracking and Analysis) is an initiative using “big data” to identify the best way to treat patients with similar disease characteristics. By precisely classifying our patients at the time of diagnosis and by implementing real-time analytical methods to interpret the data we collect, we are empowering cancer professionals with high-quality research data, creating alternative healthcare payment models, creating national benchmarks for patient outcomes, accelerating drug discovery and approval, and helping patients make informed decisions about their own care. COTA has the power to improve clinical outcomes for each patient. By optimizing treatment decision-making, we can also reduce cancer care costs along the way.
Pivotal Resources for Cancer Research
Two vital resources used by researchers at John Theurer Cancer Center are the Tumor Registry and Tissue Repository. The Tumor Registry (also called the Cancer Registry) is a source of data on all reportable tumors that are diagnosed and/or treated at our facility. The Tumor Registry is staffed by certified tumor registrars (CTR) and data management experts. They interpret and collect a wide range of demographic, diagnostic, treatment, and follow-up information on each patient.
They submit these data, as required, to state and national registries for use in research, treatment, and prevention initiatives that have the potential to benefit patients everywhere. Our physicians, researchers, and healthcare administrators rely on these data to identify cancer trends, observe how the disease presents in different populations, measure outcomes, and formulate plans to continuously improve patient care.
Our Tissue and Tumor Bank is a rich source of tissue, blood, and bone marrow samples from patients who gave their consent after undergoing biopsies, surgery, or other cancer-related procedures at John Theurer Cancer Center. Our scientists use these samples to analyze and study multiple types of cancer to learn more about how cancer develops, to develop innovative new treatments, and to predict how well a treatment can work.
You may also be interested in
A child with a primary immune deficiency has an immune system that does not work at all, or does not work well, usually due to a hereditary or genetic defect. When that happens, the child will have a reduced ability to resist or get rid of an infectious disease.
Translational research by definition brings knowledge from bench to bedside to offer as early as possible advanced options in difficult to treat cancers. This includes a strong dedication from John Theurer Cancer Center to customize treatment through precision medicine.
All patients in the Genetics Service are seen by board-certified medical geneticists and counselors in the areas of prenatal, cancer, pediatric, and adult genetics. Patients can also benefit from the expertise of all the doctors in the Hackensack University Medical Center network if treatment is required.
The Lymphoma Division at John Theurer Cancer Center involves a comprehensive team of professionals who are dedicated to treating patients with lymphoma (cancer of the immune system), which includes Hodgkin’s disease, Non-Hodgkin’s lymphoma and Chronic Lymphocytic Leukemia.